[1]范东伟,陈仲强,王宏宇.骨质疏松症和动脉硬化关系的研究进展[J].心血管病学进展,2016,(2):99-103.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.001]
　FAN Dongwei,CHEN Zhongqiang,WANG Hongyu.Correlation Between Osteoporosis and Arterial Stiffness[J].Advances in Cardiovascular Diseases,2016,(2):99-103.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.001]
点击复制

骨质疏松症和动脉硬化关系的研究进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2016年2期
页码:
99-103
栏目:
主题综述
出版日期:
2016-04-20

文章信息/Info

Title:
Correlation Between Osteoporosis and Arterial Stiffness
作者:
范东伟1; 2; 陈仲强2; 王宏宇1
1.北京大学首钢医院,北京 100144; 2.北京大学第三医院,北京 100191
Author(s):
FAN Dongwei1; 2;  CHEN Zhongqiang2;  WANG Hongyu1
1.Peking University Shougang Hospital,Beijing 100144,China; 2.Peking University Third Hospital,Beijing 100191,China
关键词:
骨质疏松;  动脉硬化;  血管钙化
Keywords:
Osteoporosis;  Arterial stiffness;  Vascular calcification
分类号:
R543.5; R681
DOI:
10.16806/j.cnki.issn.1004-3934.2016.02.001
文献标志码:
A
摘要:
在老年人群中,骨质疏松症和动脉硬化很常见,且二者的发病率随年龄增长而明显上升。近年来研究显示骨质疏松症和动脉硬化的发病相关。动物实验结果显示,动脉硬化或者钙化过程复杂,类似正常的成骨过程。例如,像骨形成发生蛋白家族、基质Gla蛋白、骨保护素等蛋白或基因既在成骨过程中发挥重要作用,又在动脉硬化或钙化过程中起作用。还有一些因素,如氧化应激、炎症、脂代谢也发挥重要作用。此外,治疗骨质疏松症的一些药物对动脉硬化也有保护作用。综上所述,现从流行病学、发病机制和临床药物治疗三方面对骨质疏松症与动脉硬化疾病关系的新进展进行阐述。
Abstract:
Osteoporosis and arterial stiffness, two multifactorial and degenerative diseases, accompany the aging process. Many studies have shown in the last years a possible correlation between arterial stiffness and osteoporosis. Animal studies show that arterial stiffness/calcification is a complex mechanism that involves similar pathways described in the normal bone osteogenesis. Genes and proteins like BMPs, MGP, osteoprotegerin play an important role at the bone level but are also highly expressed in the calcified vascular tissue. Other factors like oxidative stress, inflammation, lipids metabolism are involved in this complex process. Moreover, the medications used for treating osteoporosis also inhibit the arterial stiffness/calcification process. In this review, the recent progress of association between the two diseases in epidemology, physiopathology and treatment will be discussed.

参考文献/References:

[1] Taylor EN. Stones, bones, and cardiovascular groans[J]. Clin J Am Soc Nephrol,2015,10(2):174-176.
[2] Cunnane EM, Mulvihill JJ, Barrett HE, et al.Mechanical,biological and structural characterization of human atherosclerotic femoral plaque tissue[J]. Acta Biomater, 2015,11:295-303.
[3] Kendler DL, Bauer DC, Davison KS, et al. Vertebral Fractures: Clinical Importance and Management[J]. Am J Med, 2016,129(2):221.e1-221.e10.
[4] Mannstadt M, Lin AE,Le LP. Case records of the Massachusetts General Hospital. Case 24-2014. A 27-year-old man with severe osteoporosis and multiple bone fractures[J]. N Engl J Med,2014,371(5):465-472.
[5] Kiel DP, Kauppila LI, Cupples LA,et al. Bone loss and the progression of abdominal aortic calcification over a 25 year period: the Framingham Heart Study[J]. Calcif Tissue Int, 2001, 68(5): 271-276.
[6] Jørgensen L, Joakimsen O, Mathiesen EB,et al. Carotid plaque echogenicity and risk of nonvertebral fractures in women: a longitudinal population-based study[J]. Calcif Tissue Int, 2006,79(4): 207-213.
[7] Collins TC, Ewing SK, Diem SJ,et al. Peripheral arterial disease is associated with higher rates of hip bone loss and increased fracture risk in older men[J]. Circulation, 2009,119(17): 2305-2312.
[8] Zhou R, Zhou H, Cui M, et al. The association between aortic calcification and fracture risk in postmenopausal women in China: the prospective Chongqing osteoporosis study[J]. PLoS One, 2014,9(5): e93882.
[9] Kim NL,Suh HS. Correlation of Arterial Stiffness and Bone Mineral Density by Measuring Brachial-Ankle Pulse Wave Velocity in Healthy Korean Women[J]. Korean J Fam Med,2015,36(6): 323-327.
[10] El-Bikai R, Tahir MR, Tremblay J,et al. Association of age-dependent height and bone mineral density decline with increased arterial stiffness and rate of fractures in hypertensive individuals[J]. J Hypertens, 2015,33(4): 727-735,discussion 735.
[11] Yu XY, Li XS, Li Y,et al. Neutrophil-lymphocyte ratio is associated with arterial stiffness in postmenopausal women with osteoporosis[J]. Arch Gerontol Geriatr, 2015,61(1):76-80.
[12] Lello S, Capozzi A, Scambia G. Osteoporosis and cardiovascular disease:an update[J]. Gynecol Endocrinol, 2015,31(8): 590-594.
[13] Szulc P.Abdominal aortic calcification:a reappraisal of epidemiological and pathophysiological data[J]. Bone, 2015, 84:25-37.
[14] Wu PF,Tang JY, Li KH. RANK pathway in giant cell tumor of bone: pathogenesis and therapeutic aspects[J]. Tumour Biol, 2015,36(2):495-501.
[15] Zheng H, Wang C, He JW,et al. OPG, RANKL, and RANK gene polymorphisms and the bone mineral density response to alendronate therapy in postmenopausal Chinese women with osteoporosis or osteopenia[J]. Pharmacogenet Genomics,2016,26(1):12-19.
[16] Perez de Ciriza C, Lawrie A,Varo N. Osteoprotegerin in Cardiometabolic Disorders[J]. Int J Endocrinol, 2015,2015: 564934.
[17] Bumdelger B, Kokubo H, Kamata R,et al.Osteoprotegerin Prevents Development of Abdominal Aortic Aneurysms[J]. PLoS One, 2016,11(1):e0147088.
[18] Makarovic' S, Makarovic' Z, Steiner R,et al. Osteoprotegerin and Vascular Calcification: Clinical and Prognostic Relevance[J]. Coll Antropol, 2015,39(2): 461-468.
[19] Yamamoto M. Vascular Calcification-Pathological Mechanism and Clinical Application-. Vascular calcification as a clinical manifestation of bone-vascular axis[J]. Clin Calcium,2015, 25(5):655-660.
[20] Donate-Correa J, Martín-Núñez E, Delgado NP,et al. Implications of Fibroblast growth factor/Klotho system in glucose metabolism and diabetes[J]. Cytokine Growth Factor Rev, 2015.12.003[Epub ahead of print].
[21] Kim JH, Hwang KH, Park KS,et al. Biological Role of Anti-aging Protein Klotho[J]. J Lifestyle Med, 2015,5(1):1-6.
[22] Murali SK, Roschger P, Zeitz U, et al. FGF23 Regulates Bone Mineralization in a 1,25(OH)D and Klotho-Independent Manner[J]. J Bone Miner Res, 2016,31(1):129-142.
[23] Hao Q, Ding X, Gao L, et al. G-395A polymorphism in the promoter region of the KLOTHO gene associates with reduced cognitive impairment among the oldest old[J]. Age(Dordr), 2016,38(1):7.
[24] Okamoto Y, Fujita S, Morita H,et al. Association between circulating FGF23, alpha-Klotho, and left ventricular diastolic dysfunction among patients with preserved ejection fraction[J]. Heart Vessels, 2016, 31(1):66-73.
[25] Fukumoto S. FGF23-FGF Receptor/Klotho Pathway as a New Drug Target for Disorders of Bone and Mineral Metabolism[J]. Calcif Tissue Int, 2015,Jul 1[Epub ahead of print].
[26] Park MY, Herrmann SM, Saad A,et al. Biomarkers of kidney injury and klotho in patients with atherosclerotic renovascular disease[J]. Clin J Am Soc Nephrol, 2015,10(3): 443-451.
[27] Tsuchiya K, Nagano N,Nitta K. Klotho/FGF23 Axis in CKD[J]. Contrib Nephrol,2015,185:56-65.
[28] Yilmaz VT, Ozdem S, Donmez L,et al. FGF-23, alpha-Klotho Gene Polymorphism and Their Relationship with the Markers of Bone Metabolism in Chronic Peritoneal Dialysis Patients[J]. Eurasian J Med,2015,47(2): 115-125.
[29] Rattazzi M, Faggin E, Buso R,et al. Atorvastatin Reduces Circulating Osteoprogenitor Cells and T-Cell RANKL Expression in Osteoporotic Women: Implications for the Bone-Vascular Axis[J]. Cardiovasc Ther, 2016, 34(1): 13-20.
[30] Zhao R,Wang X,Feng F. Upregulated Cellular Expression of IL-17 by CD4+ T-Cells in Osteoporotic Postmenopausal Women[J]. Ann Nutr Metab, 2016, 68(2): 113-118.
[31] Brandenburg VM, D'Haese P, Deck A, et al. From skeletal to cardiovascular disease in 12 steps-the evolution of sclerostin as a major player in CKD-MBD[J]. Pediatr Nephrol, 2016,31(2):195-206.
[32] McClung MR, Grauer A, Boonen S,et al. Romosozumab in postmenopausal women with low bone mineral density[J]. N Engl J Med, 2014,370(5):412-20.
[33] McClung MR, Grauer A. Romosozumab in postmenopausal women with osteopenia[J]. N Engl J Med, 2014, 370(17): 1664-1665.
[34] Evenepoel P, D'Haese P,Brandenburg V. Romosozumab in postmenopausal women with osteopenia[J]. N Engl J Med,2014,370(17):1664.
[35] Wang H, Shirai K, Liu J, et al. Comparative study of cardio-ankle vascular index between Chinese and Japanese healthy subjects[J]. Clin Exp Hypertens, 2014,36(8):596-601.
[36] 王宏宇. 中国血管病变早期检测技术应用指南(2011 第二次报告)[J].心血管病学进展, 2011,32(3):318-323.
[37] Wang H, Liu J, Zhao H, et al. Arterial stiffness evaluation by cardio-ankle vascular index in hypertension and diabetes mellitus subjects[J]. J Am Soc Hypertens, 2013,7(6):426-431.
[38] Wang H. Cardio-ankle vascular index:a new marker for vascular health evaluation(experience from China)[J]. J Hum Hypertens,2015,29(2):136.
[39] Wang H, Liu J, Zhao H,et al. Relationship between cardio-ankle vascular index and N-terminal pro-brain natriuretic peptide in hypertension and coronary heart disease subjects[J]. J Am Soc Hypertens, 2014,8(9):637-643.
[40] Wang H, Liu J, Zhao H, et al. Relationship between cardio-ankle vascular index and plasma lipids in hypertension subjects[J]. J Hum Hypertens,2015,29(2):105-108.
[41] Liu J, Wang H, Zhao H, et al. Arterial stiffness is increased in healthy subjects with a positive family history of hypertension[J]. Clin Exp Hypertens, 2015,37(8): 622-626.
[42] 王宏宇,刘欢. 新的血管健康分级标准与血管医学[J].心血管病学进展, 2015,36(4): 365-368.
[43] Wee NK, Kulkarni RN, Horsnell H,et al. The brain in bone and fuel metabolism[J]. Bone, 2016,82:56-63.
[44] Devlin MJ,Rosen CJ.The bone-fat interface:basic and clinical implications of marrow adiposity[J]. Lancet Diabetes Endocrinol,2015,3(2):141-147.

相似文献/References:

[1]刘欢,王宏宇.应用踝臂指数检测四肢动脉疾病疗效[J].心血管病学进展,2015,(5):563.[doi:10.3969/j.issn.1004-3934.2015.05.010]
　LIU Huan,WANG Hongyu.Effect of Detection of Arterial Diseases on Extremities by Ankle Brachial Index[J].Advances in Cardiovascular Diseases,2015,(2):563.[doi:10.3969/j.issn.1004-3934.2015.05.010]

备注/Memo

备注/Memo:
基金项目:国家自然科学基金(30801156,81071505); 北京市石景山区科技计划项目 作者简介:范东伟(1978—),博士,主要从事骨病研究。Email:fdw@bjmu.edu.cn 通信作者:陈仲强(1958—),教授,博士,主要从事骨科疾病研究。Email:chenzq@bjmu.edu.cn 王宏宇(1967—),主任医师,博士,主要从事血管病变的临床工作及相关研究。Email:hongyuwang@188.com
更新日期/Last Update: 2016-03-25